BACKGROUND AND OBJECTIVE: The Multicenter Selective Lymphadenectomy Trial (MSLT-I) demonstrated that the sentinel node (SN) status in cutaneous melanoma affects prognosis and that completion lymphadenectomy in SN-positive patients may improve survival. Our objective was to evaluate sentinel lymph node biopsy (SLNB) in two regional hospitals in the Netherlands. METHODS: Patients with localized melanoma were planned for wide excision and SLNB. Completion lymphadenectomy was recommended for positive SN status. Data were compared with the MSLT-I. RESULTS: A median of 2 (1-7) SNs were identified in 305 patients and complications occurred in 11%. Fifty-four patients (18%) demonstrated SN metastases and 45 underwent completion lymphadenectomy (20% additional metastases). Six patients with initially negative SN developed lymph node metastases (sensitivity 90%). Overall disease-free survival was 83% (SN-negative 91% vs. SN-positive 41%; p < 0.001) and melanoma-specific survival was 93% (SN-negative 97% vs. SN-positive 62%; p < 0.001). Multivariate regression analysis revealed the SN status to be the most significant predictor for recurrence and melanoma-related death. CONCLUSION: Our results of SLNB are comparable to data from high-volume centers participating in MSLT-I. From a patient perspective, the false-negative SN rate of 10% and complication rate of 11% should be weighed against being informed about prognosis and having a possible therapeutic benefit from completion lymphadenectomy.
BACKGROUND AND OBJECTIVE: The Multicenter Selective Lymphadenectomy Trial (MSLT-I) demonstrated that the sentinel node (SN) status in cutaneous melanoma affects prognosis and that completion lymphadenectomy in SN-positive patients may improve survival. Our objective was to evaluate sentinel lymph node biopsy (SLNB) in two regional hospitals in the Netherlands. METHODS:Patients with localized melanoma were planned for wide excision and SLNB. Completion lymphadenectomy was recommended for positive SN status. Data were compared with the MSLT-I. RESULTS: A median of 2 (1-7) SNs were identified in 305 patients and complications occurred in 11%. Fifty-four patients (18%) demonstrated SN metastases and 45 underwent completion lymphadenectomy (20% additional metastases). Six patients with initially negative SN developed lymph node metastases (sensitivity 90%). Overall disease-free survival was 83% (SN-negative 91% vs. SN-positive 41%; p < 0.001) and melanoma-specific survival was 93% (SN-negative 97% vs. SN-positive 62%; p < 0.001). Multivariate regression analysis revealed the SN status to be the most significant predictor for recurrence and melanoma-related death. CONCLUSION: Our results of SLNB are comparable to data from high-volume centers participating in MSLT-I. From a patient perspective, the false-negative SN rate of 10% and complication rate of 11% should be weighed against being informed about prognosis and having a possible therapeutic benefit from completion lymphadenectomy.
Authors: J F Thompson; W H McCarthy; C M Bosch; C J O'Brien; M J Quinn; S Paramaesvaran; K Crotty; S W McCarthy; R F Uren; R Howman-Giles Journal: Melanoma Res Date: 1995-08 Impact factor: 3.599
Authors: K M McMasters; D S Reintgen; M I Ross; J E Gershenwald; M J Edwards; A Sober; N Fenske; F Glass; C M Balch; D G Coit Journal: J Clin Oncol Date: 2001-06-01 Impact factor: 44.544
Authors: John C Kang; Leslie A Wanek; Richard Essner; Mark B Faries; Leland J Foshag; Donald L Morton Journal: J Clin Oncol Date: 2005-07-20 Impact factor: 44.544
Authors: Cristina R Ferrone; Katherine S Panageas; Klaus Busam; Mary Sue Brady; Daniel G Coit Journal: Ann Surg Oncol Date: 2002-08 Impact factor: 5.344
Authors: Susanne H Estourgie; Omgo E Nieweg; Renato A Valdés Olmos; Cornelis A Hoefnagel; Bin B R Kroon Journal: Ann Surg Oncol Date: 2003-07 Impact factor: 5.344
Authors: C M Balch; S J Soong; A A Bartolucci; M M Urist; C P Karakousis; T J Smith; W J Temple; M I Ross; W R Jewell; M C Mihm; R L Barnhill; H J Wanebo Journal: Ann Surg Date: 1996-09 Impact factor: 12.969
Authors: Douglas Reintgen; Solange Pendas; James Jakub; Gray Swor; Rosemary Giuliano; Jan Bauer; Robert Cassall; Lisa Duhaime; Marwin Alsarrai; Steve Shivers Journal: Semin Oncol Date: 2004-06 Impact factor: 4.929
Authors: H Drepper; C O Köhler; B Bastian; H Breuninger; E B Bröcker; J Göhl; W Groth; P Hermanek; W Hohenberger; A Lippold Journal: Cancer Date: 1993-08-01 Impact factor: 6.860
Authors: Charles M Balch; Antonio C Buzaid; Seng-Jaw Soong; Michael B Atkins; Natale Cascinelli; Daniel G Coit; Irvin D Fleming; Jeffrey E Gershenwald; Alan Houghton; John M Kirkwood; Kelly M McMasters; Martin F Mihm; Donald L Morton; Douglas S Reintgen; Merrick I Ross; Arthur Sober; John A Thompson; John F Thompson Journal: Semin Surg Oncol Date: 2003
Authors: R M H Roumen; M S Schuurman; M J Aarts; A J G Maaskant-Braat; G Vreugdenhil; W J Louwman Journal: PLoS One Date: 2021-05-25 Impact factor: 3.240